Slide 1: Cencora, Inc. First Quarter Fiscal 2024 Earnings Call
Cencora, Inc. First Quarter Fiscal 2024 Earnings Call January 31, 2024
Slide 2: Cautionary Note Regarding Forward Looking Statements
Cautionary Note Regarding Forward Looking Statements Certain of the statements contained in this presentation are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Securit
Slide 3: 8%-12% targeted long-term adjusted diluted EPS growth
8% - 12%* targeted long - term adjusted diluted EPS growth *Growth rates given on a constant currency, ex - COVID basis Uniting under our new identity as Cencora, Long-term vision of we are better positioned to expanding leadership and grow globally and leverage growing higher-margin, our infrastruc
Slide 4: First quarter highlights & strategic overview
First quarter highlights & strategic overview Business highlights Financial highlights Fiscal 2024 guidance • Cencora’s premier global specialty • Cencora is updating its fiscal year logistics business announced $3.28 2024 financial guidance to reflect its expansion of storage capacity and cold Adju
Slide 5: Financial results
cencord Financial results
Slide 6: Q1 fiscal 2024 financial summary
Q1 fiscal 2024 Consolidated results GAAP Adjusted (non-GAAP)(1) financial summary Revenue y/y% $72.3B 15.0% $72.3B 15.0% Gross profit $2.5B $2.4B 15.0% y/y% 15.0% 12.5% Revenue growth y/y Operating expenses $1.6B $1.5B 20.7% y/y% 8.8% 8.1% Consolidated adjusted operating income growth y/y(1) Operati
Slide 7: U.S. Healthcare Solutions segment
U.S. Healthcare Solutions segment Q1 fiscal 2024 financial results Financial results Q1 Q1 y/y% fiscal 2024 fiscal 2023 • Revenue increased 15.9% to $65.2 billion due to overall market growth Revenue $65.2B $56.2B 15.9% primarily driven by unit volume growth, including increased sales of products Op
Slide 8: International Healthcare Solutions segment
International Healthcare Solutions segment Q1 fiscal 2024 financial results • Revenue increased 6.9% to $7.1 billion on an as reported basis primarily due to Constant increased sales in our European Financial results Q1 Q1 y/y% currency(1) distribution business and increased (as reported) fiscal 202
Slide 9: Fiscal 2024 guidance
cencord Fiscal 2024 guidance
Slide 10: Fiscal 2024 guidance
Fiscal 2024 guidance Constant As reported ex. Constant currency As reported currency(1) COVID-19(2) ex. COVID-19(1)(2) Consolidated Revenue 10% to 12% 10% to 12% Adjusted operating income(1) 8% to 10% 9% to 11% 11% to 13% 12% to 14% U.S. Healthcare Solutions Revenue 11% to 13% Adjusted operating inc
Slide 11: Fiscal 2024 guidance continued
Fiscal 2024 guidance continued Fiscal 2024 Guidance Fiscal 2023 Actual Adjusted diluted earnings per share(1) $13.25 to $13.50 $11.99 Interest expense $185 to $215 million $229 million Adjusted effective tax rate(1) 20% to 21% 20.3% Diluted weighted average shares outstanding 200 to 202 million 204.
Slide 12: Advancing environmental, social, and governance
Environmental Adapting to a changing climate • Near-term Science-Based Target validated by the Science Based Targets initiative • Completed business impact analyses for three of our largest businesses in the U.S., incorporating climate impact assessment results from previous years, as well as other
Slide 13: Creating differentiated value for our stakeholders
Creating differentiated value for our stakeholders Our long-term, sustainable growth is supported by investments in our people and culture and commitment to ESG Our 5 Strategic Imperatives Why we exist We are united in our responsibility to create healthier futures Advance core business Enhance capa
Slide 14: Appendix
cencord Appendix
Slide 15: GAAP to Non-GAAP Reconciliations (Three Months Ended December 31, 2023)
CENCORA, INC. GAAP TO NON-GAAP RECONCILIATIONS (in thousands, except per share data) (unaudited) Three Months Ended December 31, 2023 Net Loss Attributable to Net Income Diluted Operating Income Before Income Tax Noncontrolling Attributable Earnings Gross Profit Expenses Operating Income Income Taxe
Slide 16: GAAP to Non-GAAP Reconciliations (Three Months Ended December 31, 2022)
CENCORA, INC. GAAP TO NON-GAAP RECONCILIATIONS (in thousands, except per share data) (unaudited) Three Months Ended December 31, 2022 Net Loss (Income) Attributable to Net Income Diluted Operating Income Before Income Tax Noncontrolling Attributable Earnings Gross Profit Expenses Operating Income In
Slide 17: Supplemental information regarding non-GAAP financial measures
Supplemental information regarding non-GAAP financial measures To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses the non-GAAP financial measures described below. The non-GAAP financial measures should be viewed in
Slide 18: Supplemental information regarding non-GAAP financial measures (cont.)
Supplemental information regarding non-GAAP financial measures (cont.) • Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling interests excludes the non-controlling interest portion of the same items described above. Management be
Slide 19: Contact
Contact Bennett S. Murphy Senior Vice President Head of Investor Relations & Treasury bennett.murphy@cencora.com